Advertisement
Screener

COCRYSTAL PHARMA, INC. (COCP) Income (Loss) from Continuing Operations before Income Taxes, Domestic

1.2 / 5 stars · 14/60 Roast Me

COCRYSTAL PHARMA, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic

COCRYSTAL PHARMA, INC. (COCP) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$7.87 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.

Financial Statements › Income Statement › Pre-tax Income

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-31

  • COCRYSTAL PHARMA, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2016-09-30 was -$1.88M.
  • COCRYSTAL PHARMA, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2016-06-30 was -$3.23M.
  • COCRYSTAL PHARMA, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2015-09-30 was -$508.00K.
  • COCRYSTAL PHARMA, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2015-06-30 was -$2.57M, a 154.36% decline year-over-year.
  • COCRYSTAL PHARMA, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$7.87M.
  • COCRYSTAL PHARMA, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$15.90M.
  • COCRYSTAL PHARMA, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2011 was -$5.52M.
Period endIncome (Loss) from Continuing Operations before Income Taxes, Domestic 3 monthIncome (Loss) from Continuing Operations before Income Taxes, Domestic 6 monthIncome (Loss) from Continuing Operations before Income Taxes, Domestic 9 monthIncome (Loss) from Continuing Operations before Income Taxes, Domestic 12 month
2025-12-31-$7.87M
10-K · filed 2026-03-31
2024-12-31-$15.90M
10-K · filed 2026-03-31
2016-09-30-$1.88M
10-Q · filed 2016-11-09
-$5.11M
derived: sum of 2 quarters · filed 2016-11-09
-$9.12M
10-Q · filed 2016-11-09
2016-06-30-$3.23M
10-Q · filed 2016-08-09
-$7.24M
10-Q · filed 2016-08-09
2015-09-30-$508.00K
10-Q · filed 2016-11-09
-$3.08M
derived: sum of 2 quarters · filed 2016-11-09
-$19.62M
10-Q · filed 2016-11-09
2015-06-30-$2.57M
10-Q · filed 2016-08-09
-$19.11M
10-Q · filed 2016-08-09
2014-09-30-$2.55M
10-Q · filed 2015-11-16
$2.18M
derived: sum of 2 quarters · filed 2015-11-16
$1.81M
10-Q · filed 2015-11-16
2014-06-30$4.73M
10-Q · filed 2015-08-14
$4.36M
10-Q · filed 2015-08-14
2011-12-31-$5.52M
10-K · filed 2013-04-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
ARTELO BIOSCIENCES, INC. (ARTL)United States$0.023B
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87
NextCure, Inc. (NXTC)United States$0.024B-0.15
Rocket One Inc. (RKTO)United States$0.019B
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62